{"id":24684,"date":"2025-04-14T09:54:35","date_gmt":"2025-04-14T07:54:35","guid":{"rendered":"https:\/\/lluita.org\/lassaig-clinic-per-a-tractar-la-covid-persistent\/"},"modified":"2025-04-23T11:22:16","modified_gmt":"2025-04-23T09:22:16","slug":"clinical-trial-to-treat-persistent-covid","status":"publish","type":"post","link":"https:\/\/lluita.org\/en\/clinical-trial-to-treat-persistent-covid\/","title":{"rendered":"The clinical trial studying plasmapheresis for treating persistent COVID concludes that this technique is ineffective"},"content":{"rendered":"<p><strong><span data-preserver-spaces=\"true\">Half a hundred patients with this disease have participated in a pioneering study conducted by researchers from the Germans Trias Hospital and the Fight Infections Foundation. <\/span><\/strong>This study has clarified the usefulness of a technique that cleans the blood of inflammatory substances. Despite finding that it did not improve symptoms, the research has provided scientific evidence for patients who were trying it without any certainty.<\/p>\n<h3><strong>Conclusions of the Clinical Trial<\/strong><\/h3>\n<p><span data-preserver-spaces=\"true\">Researchers from the <a href=\"https:\/\/lluita.org\/en\/\">Fight Infections Foundation<\/a> and the Germans Trias<\/span><span data-preserver-spaces=\"true\"> i <\/span><span data-preserver-spaces=\"true\">Pujol Hospital have concluded that the plasmapheresis technique for treating persistent COVID has not been effective in the patients suffering from this disease who participated in the clinical trial initiated three years ago.<\/span><\/p>\n<p><span data-preserver-spaces=\"true\">One plausible cause of this disease is that after the acute SARS-CoV-2 infection, inflammatory substances remain in the blood, responsible for persistent symptoms. To verify this, the <strong>PAX study<\/strong>, a clinical trial proposing plasma exchange for patients with persistent <\/span><span data-preserver-spaces=\"true\">COVID<\/span><span data-preserver-spaces=\"true\"> symptoms, was launched in September 2022. <strong>This procedure involved purifying the blood of these patients to eliminate inflammatory substances responsible for the disease or clinical manifestations<\/strong>, as is done with good results in other immunological diseases.<\/span><\/p>\n<p><span data-preserver-spaces=\"true\">After three years of research, the conclusions of this study\u2014recently published in the journal <a href=\"https:\/\/www.nature.com\/articles\/s41467-025-57198-7\" target=\"_blank\" rel=\"noopener\">Nature Communications<\/a>, which highlighted it among<strong> the 50 most relevant in the world in its field<\/strong>\u2014indicate that this technique has not <\/span><span data-preserver-spaces=\"true\">provided any significant improvement in<\/span><span data-preserver-spaces=\"true\"> the symptoms that affect the quality of life of these patients.<\/span><\/p>\n<p><span data-preserver-spaces=\"true\">The<\/span><span data-preserver-spaces=\"true\"> director of the persistent COVID program at the hospital, <\/span><span data-preserver-spaces=\"true\"><strong>Lourdes Mateu<\/strong>, regrets having found that subjecting patients to<\/span><span data-preserver-spaces=\"true\"> this technique has not reduced or eliminated <\/span><span data-preserver-spaces=\"true\">their<\/span><span data-preserver-spaces=\"true\"> symptoms.<\/span><span data-preserver-spaces=\"true\"> However, Mateu emphasizes that <strong>&#8220;it will serve as scientific evidence of something that does not work, especially for those patients who, desperately, are trying any therapy against the disease they suffer from.&#8221;<\/strong><\/span><\/p>\n<h3>More than 50 participants<\/h3>\n<p><span data-preserver-spaces=\"true\">In the clinical trial\u2014pioneering and funded by the pharmaceutical company Grifols and promoted by the Fight Against Infections Foundation of the hospital\u2014<strong>50 people with persistent COVID participated<\/strong>, divided into two groups. One group underwent plasmapheresis, while the other only received physiological serum. The therapeutic plasma exchange procedure consisted of collecting plasma, separating cells and particles, and returning the rest of the blood components to the patient.<\/span><\/p>\n<p><span data-preserver-spaces=\"true\">Assignment to one of these groups was done <\/span><span data-preserver-spaces=\"true\">completely<\/span><span data-preserver-spaces=\"true\"> randomly, without the participant or the researcher knowing which group they belonged to. Six consecutive sessions were conducted\u2014either plasma exchange or serum administration\u2014and then clinical and analytical follow-up was carried out for 90 days after completing the treatment. In this regard, among other variables, possible changes in the general state of the patients and their symptoms, such as fatigue, neurocognitive performance, anxiety, or depression, were monitored.<\/span><\/p>\n<h3><strong><span data-preserver-spaces=\"true\">Testing the Efficacy of Plitidepsin<\/span><\/strong><\/h3>\n<p><span data-preserver-spaces=\"true\">Almost simultaneously with the conclusion of this trial, the <a href=\"https:\/\/lluita.org\/en\/\">Fight Infections Foundation<\/a> launched another phase II study to evaluate the safety and efficacy of a drug as a treatment for adult patients with persistent <\/span><span data-preserver-spaces=\"true\">COVID<\/span><span data-preserver-spaces=\"true\">.<\/span><\/p>\n<p><span data-preserver-spaces=\"true\">This drug is plitidepsin, an antitumor <\/span><span data-preserver-spaces=\"true\">that also has<\/span><span data-preserver-spaces=\"true\"> anti-inflammatory effects developed by the pharmaceutical company <a href=\"https:\/\/pharmamar.com\/es\/\" target=\"_blank\" rel=\"noopener\">PharmaMar<\/a> to treat various viruses, including SARS-CoV-2, MERS, Zika, respiratory syncytial virus, hepatitis C virus, and herpes virus<\/span><span data-preserver-spaces=\"true\">, among others<\/span><span data-preserver-spaces=\"true\">.<\/span><\/p>\n<p><span data-preserver-spaces=\"true\">The study, named &#8216;Thalassa,&#8217; <\/span><span data-preserver-spaces=\"true\">is<\/span><span data-preserver-spaces=\"true\"> conducted in collaboration with <a href=\"https:\/\/www.irsicaixa.es\/ca\" target=\"_blank\" rel=\"noopener\">IrsiCaixa<\/a> and has been underway since February with nearly a hundred patients from the Germans Trias Hospital.<\/span><span data-preserver-spaces=\"true\"> As in the case of the plasmapheresis trial, Lourdes Mateu reiterates that the goal of this new trial is to provide scientific evidence &#8220;<strong>that allows <\/strong><\/span><strong>better understanding of this condition and offers a specific therapeutic option to patients who currently do not have effective treatments.&#8221;<\/strong><\/p>\n<p><span data-preserver-spaces=\"true\">The reason why some patients persist with these symptoms remains unknown<\/span><span data-preserver-spaces=\"true\">, but various<\/span><span data-preserver-spaces=\"true\"> studies being conducted worldwide support different hypotheses such as viral persistence, inflammation, autoimmunity, microbiota alterations, or small blood vessel changes.<\/span><\/p>\n<p><span data-preserver-spaces=\"true\">Currently, the treatment of patients with persistent COVID focuses on alleviating symptoms and improving their quality of life; however, these interventions do not address or resolve the underlying cause of the disease.<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Half a hundred patients with this disease have participated in a pioneering study conducted by researchers from the Germans Trias Hospital and the Fight Infections Foundation. This study has clarified the usefulness of a technique that cleans the blood of inflammatory substances. Despite finding that it did not improve symptoms, the research has provided scientific [&hellip;]<\/p>\n","protected":false},"author":8,"featured_media":24682,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[2,264],"class_list":["post-24684","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized","category-covid-19-en"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.4 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>The clinical trial studying plasmapheresis for treating persistent COVID concludes that this technique is ineffective - Fundaci\u00f3 Lluita contra les Infeccions<\/title>\n<meta name=\"description\" content=\"Half a hundred patients with this disease have participated in a pioneering study conducted by researchers from the Germans Trias Hospital and the Fight Infections Foundation.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/lluita.org\/en\/clinical-trial-to-treat-persistent-covid\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"The clinical trial studying plasmapheresis for treating persistent COVID concludes that this technique is ineffective\" \/>\n<meta property=\"og:description\" content=\"Half a hundred patients with this disease have participated in a pioneering study conducted by researchers from the Germans Trias Hospital and the Fight Infections Foundation.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/lluita.org\/en\/clinical-trial-to-treat-persistent-covid\/\" \/>\n<meta property=\"og:site_name\" content=\"Fundaci\u00f3 Lluita contra les Infeccions\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-14T07:54:35+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-04-23T09:22:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/lluita.org\/custom\/uploads\/2025\/04\/Img_bloc_investigadors_PAX.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1800\" \/>\n\t<meta property=\"og:image:height\" content=\"1108\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"LLUITA Admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"LLUITA Admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/lluita.org\\\/en\\\/clinical-trial-to-treat-persistent-covid\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/lluita.org\\\/en\\\/clinical-trial-to-treat-persistent-covid\\\/\"},\"author\":{\"name\":\"LLUITA Admin\",\"@id\":\"https:\\\/\\\/lluita.org\\\/#\\\/schema\\\/person\\\/ebbfd4b21b6e55289e039158312b195a\"},\"headline\":\"The clinical trial studying plasmapheresis for treating persistent COVID concludes that this technique is ineffective\",\"datePublished\":\"2025-04-14T07:54:35+00:00\",\"dateModified\":\"2025-04-23T09:22:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/lluita.org\\\/en\\\/clinical-trial-to-treat-persistent-covid\\\/\"},\"wordCount\":674,\"image\":{\"@id\":\"https:\\\/\\\/lluita.org\\\/en\\\/clinical-trial-to-treat-persistent-covid\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/lluita.org\\\/custom\\\/uploads\\\/2025\\\/04\\\/Img_bloc_investigadors_PAX.png\",\"articleSection\":{\"1\":\"COVID-19\"},\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/lluita.org\\\/en\\\/clinical-trial-to-treat-persistent-covid\\\/\",\"url\":\"https:\\\/\\\/lluita.org\\\/en\\\/clinical-trial-to-treat-persistent-covid\\\/\",\"name\":\"The clinical trial studying plasmapheresis for treating persistent COVID concludes that this technique is ineffective - Fundaci\u00f3 Lluita contra les Infeccions\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/lluita.org\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/lluita.org\\\/en\\\/clinical-trial-to-treat-persistent-covid\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/lluita.org\\\/en\\\/clinical-trial-to-treat-persistent-covid\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/lluita.org\\\/custom\\\/uploads\\\/2025\\\/04\\\/Img_bloc_investigadors_PAX.png\",\"datePublished\":\"2025-04-14T07:54:35+00:00\",\"dateModified\":\"2025-04-23T09:22:16+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/lluita.org\\\/#\\\/schema\\\/person\\\/ebbfd4b21b6e55289e039158312b195a\"},\"description\":\"Half a hundred patients with this disease have participated in a pioneering study conducted by researchers from the Germans Trias Hospital and the Fight Infections Foundation.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/lluita.org\\\/en\\\/clinical-trial-to-treat-persistent-covid\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/lluita.org\\\/en\\\/clinical-trial-to-treat-persistent-covid\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/lluita.org\\\/en\\\/clinical-trial-to-treat-persistent-covid\\\/#primaryimage\",\"url\":\"https:\\\/\\\/lluita.org\\\/custom\\\/uploads\\\/2025\\\/04\\\/Img_bloc_investigadors_PAX.png\",\"contentUrl\":\"https:\\\/\\\/lluita.org\\\/custom\\\/uploads\\\/2025\\\/04\\\/Img_bloc_investigadors_PAX.png\",\"width\":1800,\"height\":1108,\"caption\":\"Investigadors covid persistent\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/lluita.org\\\/en\\\/clinical-trial-to-treat-persistent-covid\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Inici\",\"item\":\"https:\\\/\\\/lluita.org\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"The clinical trial studying plasmapheresis for treating persistent COVID concludes that this technique is ineffective\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/lluita.org\\\/#website\",\"url\":\"https:\\\/\\\/lluita.org\\\/\",\"name\":\"Fundaci\u00f3 Lluita contra les Infeccions\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/lluita.org\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/lluita.org\\\/#\\\/schema\\\/person\\\/ebbfd4b21b6e55289e039158312b195a\",\"name\":\"LLUITA Admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/f51e89f2d1a045d315b4e165e3eb08f2b3fd6e86e5b4f0aa29788174420124f5?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/f51e89f2d1a045d315b4e165e3eb08f2b3fd6e86e5b4f0aa29788174420124f5?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/f51e89f2d1a045d315b4e165e3eb08f2b3fd6e86e5b4f0aa29788174420124f5?s=96&d=mm&r=g\",\"caption\":\"LLUITA Admin\"},\"url\":\"https:\\\/\\\/lluita.org\\\/en\\\/author\\\/lluita\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"The clinical trial studying plasmapheresis for treating persistent COVID concludes that this technique is ineffective - Fundaci\u00f3 Lluita contra les Infeccions","description":"Half a hundred patients with this disease have participated in a pioneering study conducted by researchers from the Germans Trias Hospital and the Fight Infections Foundation.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/lluita.org\/en\/clinical-trial-to-treat-persistent-covid\/","og_locale":"en_US","og_type":"article","og_title":"The clinical trial studying plasmapheresis for treating persistent COVID concludes that this technique is ineffective","og_description":"Half a hundred patients with this disease have participated in a pioneering study conducted by researchers from the Germans Trias Hospital and the Fight Infections Foundation.","og_url":"https:\/\/lluita.org\/en\/clinical-trial-to-treat-persistent-covid\/","og_site_name":"Fundaci\u00f3 Lluita contra les Infeccions","article_published_time":"2025-04-14T07:54:35+00:00","article_modified_time":"2025-04-23T09:22:16+00:00","og_image":[{"width":1800,"height":1108,"url":"https:\/\/lluita.org\/custom\/uploads\/2025\/04\/Img_bloc_investigadors_PAX.png","type":"image\/png"}],"author":"LLUITA Admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"LLUITA Admin","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/lluita.org\/en\/clinical-trial-to-treat-persistent-covid\/#article","isPartOf":{"@id":"https:\/\/lluita.org\/en\/clinical-trial-to-treat-persistent-covid\/"},"author":{"name":"LLUITA Admin","@id":"https:\/\/lluita.org\/#\/schema\/person\/ebbfd4b21b6e55289e039158312b195a"},"headline":"The clinical trial studying plasmapheresis for treating persistent COVID concludes that this technique is ineffective","datePublished":"2025-04-14T07:54:35+00:00","dateModified":"2025-04-23T09:22:16+00:00","mainEntityOfPage":{"@id":"https:\/\/lluita.org\/en\/clinical-trial-to-treat-persistent-covid\/"},"wordCount":674,"image":{"@id":"https:\/\/lluita.org\/en\/clinical-trial-to-treat-persistent-covid\/#primaryimage"},"thumbnailUrl":"https:\/\/lluita.org\/custom\/uploads\/2025\/04\/Img_bloc_investigadors_PAX.png","articleSection":{"1":"COVID-19"},"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/lluita.org\/en\/clinical-trial-to-treat-persistent-covid\/","url":"https:\/\/lluita.org\/en\/clinical-trial-to-treat-persistent-covid\/","name":"The clinical trial studying plasmapheresis for treating persistent COVID concludes that this technique is ineffective - Fundaci\u00f3 Lluita contra les Infeccions","isPartOf":{"@id":"https:\/\/lluita.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/lluita.org\/en\/clinical-trial-to-treat-persistent-covid\/#primaryimage"},"image":{"@id":"https:\/\/lluita.org\/en\/clinical-trial-to-treat-persistent-covid\/#primaryimage"},"thumbnailUrl":"https:\/\/lluita.org\/custom\/uploads\/2025\/04\/Img_bloc_investigadors_PAX.png","datePublished":"2025-04-14T07:54:35+00:00","dateModified":"2025-04-23T09:22:16+00:00","author":{"@id":"https:\/\/lluita.org\/#\/schema\/person\/ebbfd4b21b6e55289e039158312b195a"},"description":"Half a hundred patients with this disease have participated in a pioneering study conducted by researchers from the Germans Trias Hospital and the Fight Infections Foundation.","breadcrumb":{"@id":"https:\/\/lluita.org\/en\/clinical-trial-to-treat-persistent-covid\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/lluita.org\/en\/clinical-trial-to-treat-persistent-covid\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/lluita.org\/en\/clinical-trial-to-treat-persistent-covid\/#primaryimage","url":"https:\/\/lluita.org\/custom\/uploads\/2025\/04\/Img_bloc_investigadors_PAX.png","contentUrl":"https:\/\/lluita.org\/custom\/uploads\/2025\/04\/Img_bloc_investigadors_PAX.png","width":1800,"height":1108,"caption":"Investigadors covid persistent"},{"@type":"BreadcrumbList","@id":"https:\/\/lluita.org\/en\/clinical-trial-to-treat-persistent-covid\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Inici","item":"https:\/\/lluita.org\/en\/"},{"@type":"ListItem","position":2,"name":"The clinical trial studying plasmapheresis for treating persistent COVID concludes that this technique is ineffective"}]},{"@type":"WebSite","@id":"https:\/\/lluita.org\/#website","url":"https:\/\/lluita.org\/","name":"Fundaci\u00f3 Lluita contra les Infeccions","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/lluita.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/lluita.org\/#\/schema\/person\/ebbfd4b21b6e55289e039158312b195a","name":"LLUITA Admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/f51e89f2d1a045d315b4e165e3eb08f2b3fd6e86e5b4f0aa29788174420124f5?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/f51e89f2d1a045d315b4e165e3eb08f2b3fd6e86e5b4f0aa29788174420124f5?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f51e89f2d1a045d315b4e165e3eb08f2b3fd6e86e5b4f0aa29788174420124f5?s=96&d=mm&r=g","caption":"LLUITA Admin"},"url":"https:\/\/lluita.org\/en\/author\/lluita\/"}]}},"_links":{"self":[{"href":"https:\/\/lluita.org\/en\/wp-json\/wp\/v2\/posts\/24684","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lluita.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lluita.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lluita.org\/en\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/lluita.org\/en\/wp-json\/wp\/v2\/comments?post=24684"}],"version-history":[{"count":6,"href":"https:\/\/lluita.org\/en\/wp-json\/wp\/v2\/posts\/24684\/revisions"}],"predecessor-version":[{"id":24752,"href":"https:\/\/lluita.org\/en\/wp-json\/wp\/v2\/posts\/24684\/revisions\/24752"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/lluita.org\/en\/wp-json\/wp\/v2\/media\/24682"}],"wp:attachment":[{"href":"https:\/\/lluita.org\/en\/wp-json\/wp\/v2\/media?parent=24684"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lluita.org\/en\/wp-json\/wp\/v2\/categories?post=24684"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}